Abstract:Satoru Miura, 1 Hyun Ae Jung, 2 Shin Yup Lee, 3 Seung Hyeun Lee, 4 Min Ki Lee, 5 Yong Chul Lee, 6 Maximilian J Hochmair, 7 Cheng-Ta Yang, 8 Angela Märten, 9 James Chih-Hsin Yang, 10 Sanjay Popat 11, 12 1 Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan; 2 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 3 Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea; 4 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, South Korea; 5 Department of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea; 6 Department of Internal Medicine, Research Center for Pulmonary Disorders, Jeonbuk National University Medical School, Jeonju, South Korea; 7 Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Vienna, Austria; 8 Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan; 9 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 10 Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; 11 Lung Unit, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; 12 The Institute of Cancer Research, London, United Kingdom Correspondence: Sanjay Popat, Lung Unit, Royal Marsden National Health Service Foundation Trust, 203 Fulham Road, Chelsea, London, SW3 6JJ, United Kingdom, Tel +44-20-7808-2132, Email Objective: Two recent non-interventional trials, GioTag and UpSwinG, demonstrated encouraging time-to-treatment failure (TTF) and overall survival (OS) in patients with epidermal growth factor receptor ( EGFR) mutation-positive non-small cell lung cancer (NSCLC) (Del19 or L858R) who received sequential afatinib/osimertinib, especially in Asians. Here, we have undertaken a combined analysis of Asian patients from both studies. Materials and Methods: Existing medical/electronic records were identified for consecutive EGFR-tyrosine kinase inhibitor (TKI)-naïve patients who received first-line afatinib/second-line osimertinib in "real-world" practice (all T790M-positive). Patients with active brain metastases were excluded. The primary objective was TTF. OS was a key secondary objective. Results: One hundred and sixty-eight patients were analyzed. Most patients were recruited from South Korea or Japan (52/21%). At the start of afatinib, median age (range) was 61.5 years (35– 88), 58% were female, Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1/≥ 2) was 29/62/9%, 17% had brain metastases, and EGFR mutation status (Del19/L858R) was 65/35%. At the start of osimertinib, ECOG PS (0/1/≥ 2) was 22/61/17% and 14% had brain metastases. Median TTF and OS were 30.0 months (95% CI: 24.5– 32.5) and 45.2 months (95% CI: 41.7– 71.1), respectively. Median OS was 63.5 months in patients with a Del19 mutation. Median OS in patients with brain metastases or ECOG PS ≥ 2 was 26.4 and 33.1 months, respectively. Conclusion: Sequential afatinib/osimertinib showed encouraging activity in Asian patients with EGFR mutation-positive NSCLC and T790M-mediated acquired resistance, especially those with Del19-positive disease. Activity was observed across "real-world" patients including those with poor ECOG PS and/or brain metastases. ECOG PS and incidence of brain metastases remained stable prior to, and after, afatinib. Graphical Keywords: EGFR, afatinib, osimertinib, sequential, T790M Graphical Three generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) are available for the first-line treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC): the first-generation reversible EGFR TKIs (erlotinib and gefitinib), the second-generation ErbB family blockers (afatinib and dacomitinib) and the third-generation irreversible EGFR TKI, osimertinib. 1 The head-to-head randomized trials, LUX-Lung 7, 2 ARCHER-1050, 3 and FLAURA 4 have shown that afatinib, dacomitinib and osimertinib confer significant clinical benefit versus first-generation EGFR TKIs. However, second- and third-generation EGFR TKIs have never bee -Abstract Truncated-

Sequencing of Therapy Following First-Line Afatinib in Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.

PS02.20 Subsequent Therapies Post-Afatinib among Patients with EGFR Mutation-Positive (egfrm+) NSCLC in LUX-Lung 3, 6 and 7

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations

A Consensus on the Role of Osimertinib in Non-Small Cell Lung Cancer from the AME Lung Cancer Collaborative Group

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial

Interim Analysis of Afatinib Monotherapy in Patients with Metastatic Nsclc Progressing after Chemotherapy and Erlotinib/Gefitinib (E/G) in A Trial of Afatinib Plus Paclitaxel Versus Investigator'S Choice Chemotherapy Following Progression on Afatinib Monotherapy

OA23.05 First-Line Afatinib Versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

First-Line Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

Afatinib Versus Gefitinib As First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-cell Lung Cancer (Lux-Lung 7): a Phase 2B, Open-Label, Randomised Controlled Trial

P1.14-62 Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIIb Studies

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

P1.34: First-Line Afatinib Vs Gefitinib for Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: the LUX-Lung 7 Trial: Track: Advanced NSCLC.

Afatinib As First-line Treatment of Older Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (Lux-Lung 3 and LUX-Lung 6)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations